文献速递淋巴瘤

早期霍奇金淋巴瘤联合模式治疗的真实世界研究:治疗不足影响结局

A real-world study of combined modality therapy for early-stage Hodgkin lymphoma: too little treatment impacts outcome.
PubMed 文献 · Blood Adv · 2022-01-01

这项回顾性多中心队列研究比较了2010年1月至2020年12月治疗的125例早期经典型霍奇金淋巴瘤(IA-IIB期)患者接受联合模式治疗(CMT,n=63)与单纯化疗(n=62)的结局,中位随访59.8个月(95%CI 48.6-71.0)。两组总生存无差异(5年OS:CMT 98.0% vs 单纯化疗 95.1%,P=.38),但单纯化疗组无进展生存降低(2年PFS:CMT 95.1% vs 单纯化疗 75.3%,P=.005),在 bulky、不利特征或PET2阳性亚组中同样降低。作者认为CMT似乎对早期cHL有益,尤其PET2阳性和不利疾病患者; favourable、非bulky或PET2阴性患者单纯化疗可获得相当结局。

要点

  • 早期cHL患者中,单纯化疗较CMT的2年PFS降低(CMT 95.1% vs 单纯化疗 75.3%,P=.005)。
  • bulky、不利特征或PET2阳性亚组中,单纯化疗的PFS较CMT降低。
  • favourable、非bulky或PET2阴性患者中,单纯化疗与CMT的PFS无显著差异。

核心结论

  • 基于真实世界经验,CMT似乎对早期cHL患者有益,尤其是PET2阳性和不利疾病患者。
  • favourable、非bulky或PET2阴性患者接受单纯化疗可获得相当结局。
  • 临床试验结果在部分患者亚组中可重现,但不符合试验标准的其他亚组在排除放疗后结局较差。

研究设计与样本

  • 回顾性、多中心队列研究,比较CMT与单纯化疗治疗早期cHL(IA-IIB期)。
  • 患者治疗时间为2010年1月至2020年12月。
  • 共125例患者,CMT组n=63,单纯化疗组n=62。
  • 化疗第2周期后PET(PET2)由核放射科医生独立审阅,Deauville评分≥4分为阳性,≤3分为阴性。
  • 采用意向性治疗分析比较患者结局。

主要发现

  • 中位随访59.8个月(95%CI 48.6-71.0),两组总生存无差异(5年OS:CMT 98.0% vs 单纯化疗 95.1%;log-rank检验P=.38)。
  • 全部患者中单纯化疗组无进展生存降低(2年PFS:CMT 95.1% vs 单纯化疗 75.3%;log-rank检验P=.005)。
  • bulky疾病患者(n=43)中单纯化疗组PFS降低(log-rank检验P<.001)。
  • 不利疾病患者(n=81)中单纯化疗组PFS降低(log-rank检验P=.002)。
  • PET2阳性患者(n=15)中单纯化疗组PFS降低(log-rank检验P=.02)。

关键数值与推荐

  • 非bulky疾病患者中两组PFS无显著差异(log-rank检验P=.35)。
  • favourable疾病患者中两组PFS无显著差异(log-rank检验P=.62)。
  • PET2阴性患者中两组PFS无显著差异(log-rank检验P=.19)。

临床怎么用

  • 作者认为CMT似乎对早期cHL患者有益,尤其是PET2阳性和不利疾病患者。
  • 作者认为 favourable、非bulky或PET2阴性患者接受单纯化疗可获得相当结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Multiple clinical trials have assessed de-escalation strategies from combined modality therapy (CMT) to chemotherapy-alone for the treatment of early-stage classical Hodgkin lymphoma (cHL), confirming similar outcomes. The application of these data to the real-world is limited, however. We conducted a retrospective, multicenter cohort study comparing CMT vs chemotherapy-alone in patients with early-stage cHL (stage IA-IIB) treated between January 2010 and December 2020. Positron emission tomography (PET) scans after chemotherapy cycle 2 (PET2) were independently reviewed by a nuclear radiologist (Deauville score ≥4, positive; ≤3, negative). Patient outcomes were compared by using an intention-to-treat analysis. Among 125 patients (CMT, n = 63; chemotherapy-alone, n = 62) with a median follow-up of 59.8 months (95% CI, 48.6-71.0), no differences in overall survival were observed (5-year overall survival, CMT 98.0% vs chemotherapy-alone 95.1%; log-rank test, P = .38). However, there was reduced progression-free survival (PFS) with chemotherapy-alone among all patients (2-year PFS, CMT 95.1% vs chemotherapy-alone 75.3%; log-rank test, P = .005) and in those with bulky (n = 43; log-rank test, P < .001), unfavorable (n = 81; log-rank test, P = .002), or PET2-positive (n = 15; log-rank test, P = .02) disease. No significant differences in PFS were seen for patients with non-bulky (log-rank test, P = .35), favorable (log-rank test, P = .62), or PET2-negative (log-rank test, P = .19) disease. Based on our real-world experience, CMT seems beneficial for patients with early-stage cHL, especially those with PET2-positive and unfavorable disease. Chemotherapy-alone regimens can lead to comparable outcomes for patients with favorable, non-bulky, or PET2-negative disease. We conclude that although results seen in clinical trials are replicated in certain patient subgroups, other subgroups not fitting trial criteria do poorly when radiotherapy is excluded.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Chohan KL, Young JR, Lester S, et al. A real-world study of combined modality therapy for early-stage Hodgkin lymphoma: too little treatment impacts outcome. Blood Adv. 2022. PMID: 35617689. doi:10.1182/bloodadvances.2022007363

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。